IRadimed anticipates third-quarter revenue of $23 million to $24.5 million as it more than doubles production of its new 3870 MR IV pump system to over 300 units. The company reported second-quarter revenue of $20.5 million, up 0.5% from a year earlier, with gross margin declining to 74% from 78% due to higher manufacturing costs tied to the first sizable production ramp of the 3870. Bookings in the quarter were more than double the units shipped, and 70% of those orders were for the 4-channel quad pump system, which carries an average selling price north of $110,000. Management reaffirmed full-year 2026 revenue guidance of $91 million to $96 million and raised the non-GAAP diluted earnings per share range to $2.09 to $2.24. The company expects start-up costs experienced in the second quarter to be better than 50% reduced in the third quarter, though lead times for new quad orders are extending toward four to six months amid strong demand.
Iradimed CoBookings more than double units shipped, with strong demand for quad pump system.